All FAQ claims

DXM FAQ 1997: selective audit by topic

A selective audit: 29 claims. Links within each card lead to the topic pages.

29 / 29

DXM and DXO are both pharmacologically active

This point remains valid. Modern evidence clarifies differences between their targets and the contribution of metabolism to effects.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Studies altering CYP2D6 activity show that shifts in the balance of DXM and DXO change the profile of subjective responses. Xiao’s paper compares target binding in vitro.

Limits of the conclusion: Each substance’s contribution depends on exposure and the study endpoint. Binding data concern the biological system studied; their relevance to effects in humans remains uncertain.

Sources: Zawertailo — metabolism and effects Zawertailo — CYP2D6 inhibition Xiao — DXM and DXO target binding

Historical paraphrase · FAQ 4.0 · 1997 · §5.15 White already described the activity of DXM itself and its metabolite DXO.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §5.15 · Why does DXM Affect Different People So Differently?

CYP2D6 converts DXM to DXO

The main pathway is described correctly. Conversion rates vary with genetic variants of the enzyme and drug inhibition.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Capon’s pharmacokinetic study and Rüdesheim’s model link CYP2D6 activity to DXM exposure. Zawertailo’s studies also examine subjective effects.

Limits of the conclusion: Interpretation depends on formulation, concomitant medicines and the measure being examined.

Sources: Rüdesheim — pharmacokinetic model Capon — CYP2D6 activity Zawertailo — metabolism and effects Zawertailo — CYP2D6 inhibition

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 The FAQ links DXO formation to CYP2D6.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Poor metabolism and the pattern of effects

With reduced CYP2D6 activity, DXM exposure can increase substantially. The experience also changes: a small study reported greater sedation, dysphoria and psychomotor impairment.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Capon examined pharmacokinetics in poor and extensive metabolizers; Zawertailo’s pilot study compared their subjective and psychomotor responses.

Limits of the conclusion: The finding applies to the conditions of these small studies. Genotype accounts for part of the variability, while individual responses also depend on other factors.

Sources: Capon — CYP2D6 activity Zawertailo — metabolism and effects

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 The FAQ suggests that DXM has weaker effects in poor metabolizers.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Modern metabolizer categories

Modern terminology distinguishes PM, IM, NM and UM: poor, intermediate, normal and ultrarapid metabolism. Functional activity of variants and the effects of medicines on actual enzyme activity are considered.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Caudle’s consensus standardizes translation of CYP2D6 genotype into phenotype; Rüdesheim’s model applies modern categories to DXM pharmacokinetics.

Limits of the conclusion: The historical label EM requires checking the definition used in the particular study. Enzyme inhibitors can alter the functional phenotype, a process called phenoconversion.

Sources: Rüdesheim — pharmacokinetic model Caudle — CYP2D6 genotype and phenotype

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 White describes differences in CYP2D6 activity and people with extra gene copies.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Correcting an arrow in the metabolic scheme

This pathway starts with DXM: N-demethylation produces 3-methoxymorphinan. The corresponding pathway for DXO leads to 3-hydroxymorphinan.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Schemes in Lutz’s and Rüdesheim’s papers distinguish O-demethylation from N-demethylation and subsequent processing of metabolites.

Limits of the conclusion: A specific connection in the scheme is corrected. The FAQ’s other valid descriptions of DXO formation remain applicable.

Sources: William White — historical DXM FAQ Lutz — DXM metabolism Rüdesheim — pharmacokinetic model

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 One sentence in the FAQ attributes formation of 3-methoxymorphinan to DXO.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Further processing of DXO

A modern scheme also includes DXO glucuronidation. Results should distinguish unconjugated DXO, total DXO and the protein-unbound fraction.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Lutz’s paper examines how CYP-dependent and subsequent pathways affect assessment of metabolism; Rüdesheim’s model accounts for processing of DXM and DXO.

Limits of the conclusion: The meaning of a measurement depends on the analytical method. Concentrations can be compared after identifying which form of the substance was measured.

Sources: Lutz — DXM metabolism Rüdesheim — pharmacokinetic model

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 The FAQ focuses on the two main demethylation pathways.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

PCP2 and the dopamine hypothesis

PCP2 is an older label for binding sites. Its association with DAT and its use to explain the first plateau remain hypotheses.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Meoni studied dextromethorphan binding sites in rat brain and obtained evidence linking part of the observations to serotonin transport. Xiao’s modern paper examines several known targets.

Limits of the conclusion: Establishing a molecular target requires independent evidence on the identity of the site and the function of the protein.

Sources: Xiao — DXM and DXO target binding Meoni — DM2 binding sites

Historical paraphrase · FAQ 4.0 · 1997 · §9.2.2 White proposed a link between PCP2 and dopamine reuptake.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.2 · Contribution of the PCP2 Binding Site

The second binding site: what was clarified

DM2 findings are better described through the conditions of the particular experiment. Some older observations are consistent with sites associated with serotonin transport.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: In Meoni’s rat-brain study, binding was sodium-dependent; distribution and mutual displacement with paroxetine supported an association with the serotonin uptake system.

Limits of the conclusion: The older labels grouped different experimental observations. Each site requires its own molecular identification.

Sources: Meoni — DM2 binding sites

Historical paraphrase · FAQ 4.0 · 1997 · §9.2.1 The FAQ links the second DXM binding site to PCP2 with near certainty.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.1 · General Information

Sigma receptors gained a molecular description

The structure of sigma-1 was later published, and sigma-2 was identified as TMEM97. These discoveries update the older description.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Schmidt presented the crystal structure of human sigma-1. Alon showed that TMEM97 corresponds to sigma-2.

Limits of the conclusion: Molecular descriptions help investigate receptor functions. Receptor function and a particular subjective effect belong to different levels of description.

Sources: Schmidt — sigma-1 structure Alon — sigma-2 and TMEM97

Historical paraphrase · FAQ 4.0 · 1997 · §10.2 The FAQ reflects early uncertainty about the cellular location and nature of sigma receptors.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2 · What are Sigma Receptors?

Sigma receptors and unusual sensations of movement

This explanation remains a hypothesis. Sigma-1 findings in experimental models and prescription labeling concern other endpoints.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Nguyen examined antidepressant-like effects of DXM in a mouse model. The Auvelity label describes DXM’s pharmacological targets and notes uncertainty about the mechanism of therapeutic action.

Limits of the conclusion: A mouse behavioral model and human subjective experiences require different methods of evaluation.

Sources: Nguyen — mouse model Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §10.2.1.2 White linked unusual sensations of movement to sigma activity.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2.1.2 · Location and Function in the Brain

The historical sigma-3 label

This audit retains sigma-3 as a historical label. The modern molecular classification in the cited sources centers on sigma-1 and sigma-2.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Schmidt’s structural work and Alon’s identification of TMEM97 provide testable grounds for the modern names.

Limits of the conclusion: The audit’s source coverage is limited. A separate new target requires confirmed molecular identification.

Sources: William White — historical DXM FAQ Schmidt — sigma-1 structure Alon — sigma-2 and TMEM97

Historical paraphrase · FAQ 4.0 · 1997 · §10.2.3 The FAQ mentions sigma-3 as a recently discovered site.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2.3 · Sigma 3 Receptors

Endopsychosin: an unresolved hypothesis

In the audit, this remains an unconfirmed historical hypothesis. It offers a weak basis for explaining modern DXM findings.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: For this row, the audit cites the FAQ itself. Its bibliography contains no separate modern primary confirmation.

Limits of the conclusion: This describes the sources in the audit’s bibliography; a comprehensive literature search on the hypothesis lies outside its scope.

Sources: William White — historical DXM FAQ

Historical paraphrase · FAQ 4.0 · 1997 · §10.7 White discussed a proposed endogenous ligand called endopsychosin.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.7 · Endopsychosin and the Big Picture

The role of NMDA in dissociative effects

The main association remains valid. DXM and DXO differ in binding profiles, while each target’s precise contribution to human effects remains a research question.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Carbonaro’s and Shram’s papers describe controlled studies of DXM effects in humans. Xiao provides in-vitro binding data; the Auvelity label includes NMDA in its pharmacology description.

Limits of the conclusion: Plasma concentration, laboratory affinity and receptor occupancy in the brain are different measures. Relating them requires an appropriate model and data.

Sources: Xiao — DXM and DXO target binding Carbonaro — DXM effects in humans Shram — ketamine comparison Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §9.2.4 The FAQ gives NMDA an important role in dissociative effects.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.4 · Contribution of the NMDA Receptor

Plateaus as descriptions of experience

These categories help describe reports of experience. Their boundaries vary with metabolism, formulation, combinations and individual characteristics.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: CYP2D6 studies and changes in the DXM/DXO balance show qualitative variability in responses. This calls for caution when applying the historical classification to an individual.

Limits of the conclusion: Clinical conclusions require measured exposures and endpoints. A plateau description remains a subjective category.

Sources: William White — historical DXM FAQ Rüdesheim — pharmacokinetic model Zawertailo — metabolism and effects Zawertailo — CYP2D6 inhibition

Historical paraphrase · FAQ 4.0 · 1997 · §9.3.1 The FAQ distinguishes plateaus and allows intermediate states.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.3.1 · Plateaus 1-3: Multiple Receptors

The receptor activation ladder

The scheme is best retained as a historical model. DXM and DXO concentrations, binding and functional effects describe different aspects of the substances’ actions.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Xiao compares DXM and DXO targets in vitro. These measurements differ from receptor-occupancy data in the living brain.

Limits of the conclusion: The original scheme was a qualitative proposal. This audit provides no established thresholds for sequential target activation across plateaus.

Sources: William White — historical DXM FAQ Xiao — DXM and DXO target binding

Historical paraphrase · FAQ 4.0 · 1997 · §9.3.1 White proposed a qualitative sequence of target involvement, including PCP2, and qualified it as approximate.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.3.1 · Plateaus 1-3: Multiple Receptors

A direct comparison of DXM and ketamine

A controlled study now includes a direct comparison with DXM. It examined abuse potential and subjective effects under specific conditions.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: In Shram’s paper, the principal comparison concerned ketamine and placebo; DXM served as an additional exploratory comparator.

Limits of the conclusion: The results apply to the selected participants, administration routes and measures. Comparing all forms and varieties of dissociative experience remains a broader task.

Sources: Shram — ketamine comparison

Historical paraphrase · FAQ 4.0 · 1997 · §10.6 The FAQ notes limits to the similarity between DXM and ketamine.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.6 · How Does DXM Compare to Other Dissociatives at These Receptors?

Serotonin toxicity: clinical cases

Serotonin toxicity involving DXM is described in clinical publications. It should be presented as a documented complication, particularly in combinations with serotonergic agents.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Monte reviews overdose cases involving products with DXM and chlorpheniramine. Harada describes a fatal case involving overdose of DXM and moclobemide. The Auvelity label also carries a warning.

Limits of the conclusion: Clinical cases establish that the complication can occur; its frequency across all doses and combinations is difficult to determine from them.

Sources: Monte — serotonin toxicity Harada — DXM and moclobemide Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §6.2.9 The FAQ places serotonin syndrome under a theoretical heading, although its text already discusses hazardous combinations.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.2.9 · Serotonin Syndrome

The warning about MAO inhibitors

The warning remains applicable and deserves prominent presentation. Modern clinical reports and prescription labeling add to the historical basis.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Harada describes a fatal case involving moclobemide. The Auvelity label contraindicates combination with MAO inhibitors and includes specific provisions for linezolid and intravenous methylene blue.

Limits of the conclusion: Specific medicine restrictions are checked against the current label for the product concerned. This section examines the historical text.

Sources: William White — historical DXM FAQ Harada — DXM and moclobemide Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §6.2.9 White already warned of a potentially fatal combination of DXM with MAO inhibitors.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.2.9 · Serotonin Syndrome

Antidepressants: two interaction pathways

It is important to distinguish changes in DXM exposure from the combination’s serotonergic effects. Both pathways matter for fluoxetine and paroxetine.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Chyka’s clinical guideline accounts for interacting medicines; the Auvelity label includes a serotonin-syndrome warning and information about CYP2D6 inhibition.

Limits of the conclusion: The pathways can coexist. Their contribution depends on the particular medicine, regimen and other ingredients.

Sources: Monte — serotonin toxicity Chyka — clinical poisoning guideline Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §9.5.1 The FAQ describes CYP2D6 inhibition by fluoxetine.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5.1 · Factors Affecting Metabolism of DXM

Diphenhydramine: an overly broad safety judgment

That broad judgment should be removed. Diphenhydramine’s own sedative and antimuscarinic effects matter, as does its inhibition of CYP2D6.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Hamelin demonstrated effects of diphenhydramine on CYP2D6-dependent metoprolol metabolism in humans. Chyka’s guideline calls for considering accompanying ingredients in DXM poisoning.

Limits of the conclusion: Hamelin’s study used metoprolol. Quantifying the interaction directly with DXM requires its own data.

Sources: Hamelin — diphenhydramine and CYP2D6 Chyka — clinical poisoning guideline

Historical paraphrase · FAQ 4.0 · 1997 · §6.1.3 The FAQ describes the combination with diphenhydramine as probably safe.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.1.3 · Mild Allergic Reactions and Histamine Release

Bromism: the direction of the anion-gap change

The characteristic diagnostic clue in the reported case is falsely high chloride and a low or negative anion gap. Bromide interference with chloride measurement explains it.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Ng describes chronic use of syrup containing DXM hydrobromide and acetaminophen, pseudohyperchloremia and a negative anion gap.

Limits of the conclusion: The laboratory effect depends on the measurement method. Interpretation requires the product’s ingredients and clinical context.

Sources: Ng — bromism

Historical paraphrase · FAQ 4.0 · 1997 · §6.3.15 The FAQ associates bromism with an increased anion gap.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.3.15 · Bromide Poisoning

The anion gap and a bromide assay

The anion gap is calculated from electrolytes. It can provide a clue when bromism is suspected; bromide concentration is measured by a separate assay.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Ng’s clinical case links unusual chloride and anion-gap findings to bromism and the laboratory measurement method.

Limits of the conclusion: The finding requires clinical interpretation that accounts for possible causes and the analytical method.

Sources: Ng — bromism

Historical paraphrase · FAQ 4.0 · 1997 · §6.8.3 The FAQ effectively equates the anion gap with a bromide test.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.8.3 · Build-Down

Naloxone: a limited clinical role

Clinical guidance allows consideration of naloxone in marked sedation or coma, particularly with respiratory depression. The overall response in DXM intoxication remains unpredictable.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Chyka’s consensus guideline assigns this recommendation Grade C. It addresses poisoning management and patient referral.

Limits of the conclusion: Use belongs within medical care. This section explains the evidence without providing a self-treatment protocol.

Sources: Chyka — clinical poisoning guideline

Historical paraphrase · FAQ 4.0 · 1997 · §6.10 The FAQ presents intravenous naloxone as an antidote for DXM poisoning.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.10 · How Toxic is DXM, and What is the Lethal Dose?

Dependence and withdrawal

Clinical cases of dependence, tolerance and withdrawal were published later. Their descriptions make the older section more specific.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Mutschler describes dependence and withdrawal; Olives describes long-term use with repeated intoxications and tolerance.

Limits of the conclusion: These are individual clinical observations. Prevalence, timing and severity across users require broader evidence.

Sources: Mutschler — dependence and withdrawal Olives — prolonged use and tolerance

Historical paraphrase · FAQ 4.0 · 1997 · §6.7 White discusses dependence problems and possible DXM withdrawal.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.7 · Is DXM Withdrawal Dangerous?

Where the claimed limit of 50 came from

The description is best retained with its origin and uncertainty. The threshold for changes in effects remains uncertain in the audit.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Mutschler’s and Olives’s clinical cases document dependence and tolerance with prolonged use, but concern individual patients.

Limits of the conclusion: The number 50 belongs to the historical account. Prediction from the number of episodes requires systematic data.

Sources: William White — historical DXM FAQ Mutschler — dependence and withdrawal Olives — prolonged use and tolerance

Historical paraphrase · FAQ 4.0 · 1997 · §7.6 The FAQ discusses a limit of 50 uses as an anecdotal and variable observation.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §7.6 · What is the "50 Trip Limit" and How Can I Avoid It?

Neurotoxicity: distinguish the types of evidence

Animal experiments, human MRI associations and claims of specific neuronal damage require separate interpretation. In 2004, White withdrew claims from his 1998 neurotoxicity text.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Carliss and Tran examined different administration routes and endpoints in rats. Qiu compared MRI findings in people dependent on DXM and a control group. White’s response records withdrawal of his earlier conclusions.

Limits of the conclusion: Transferring animal pathology to humans requires evidence. MRI associations allow several explanations; Olney lesions in humans after DXM have not been established in the reviewed sources.

Sources: Carliss — oral DXM in rats Tran — cellular changes in rats White — withdrawal of neurotoxicity claims Qiu — MRI in DXM dependence

Historical paraphrase · FAQ 4.0 · 1997 · §6.3.1 The FAQ discusses reports of lasting impairment and their resemblance to descriptions of Olney lesions. White later strengthened these claims in a separate text.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.3.1 · NMDA Antagonist Neurotoxicity (Olney's Lesions)

Immediate and extended release

A modern description should name the formulation explicitly. DXM hydrobromide and polistirex have different profiles; absorption timing depends on the product and conditions.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: The Delsym label describes an extended-release polistirex suspension. The Auvelity label distinguishes immediate-release DXM from extended-release bupropion.

Limits of the conclusion: Read the active-ingredient amount on the label together with the stated salt and formulation. Assessing bromide requires the actual product composition.

Sources: Delsym — polistirex label Chyka — clinical poisoning guideline Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 The FAQ discusses rapid absorption of the ordinary formulation and prolonged release of polistirex.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Combination products: every ingredient matters

Assessment should use the complete ingredient list. Antihistamines, acetaminophen and other components have their own risks, which depend on the substance and exposure.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Monte examines serotonin toxicity in overdose involving DXM and chlorpheniramine. Chyka’s guideline separately requires consideration of accompanying product ingredients.

Limits of the conclusion: A subjective plateau category offers little help in assessing toxicity of additional ingredients. Their names and amounts are needed.

Sources: Monte — serotonin toxicity Chyka — clinical poisoning guideline

Historical paraphrase · FAQ 4.0 · 1997 · §6.1.3 The FAQ allows products with antihistamine ingredients below a particular plateau.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.1.3 · Mild Allergic Reactions and Histamine Release

Therapeutic uses: specific combinations

The modern picture includes a prescription combination of DXM and bupropion: Auvelity has a US indication for major depressive disorder in adults. In 2026, the FDA added agitation associated with dementia due to Alzheimer’s disease.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: The current label describes a specific combination product and clinical studies supporting its indications. Bupropion increases DXM exposure through CYP2D6 inhibition.

Limits of the conclusion: The conclusion concerns the product composition and indications studied. The label describes DXM’s therapeutic mechanism as unclear.

Sources: Auvelity — current label FDA — new Auvelity indication

Historical paraphrase · FAQ 4.0 · 1997 · §6.8 The FAQ is skeptical about dissociative substances as treatments for depression.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.8 · Kicking the DXM Habit: What to Do If You are Addicted

Audit references
  1. William White — historical DXM FAQ — Historical archive

    The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.

  2. Lutz — DXM metabolism — PubMed abstract
  3. Rüdesheim — pharmacokinetic model — PubMed abstract
  4. Capon — CYP2D6 activity — PubMed abstract
  5. Caudle — CYP2D6 genotype and phenotype — PubMed abstract
  6. Zawertailo — metabolism and effects — PubMed abstract
  7. Zawertailo — CYP2D6 inhibition — PubMed abstract
  8. Xiao — DXM and DXO target binding — Selected paper sections

    The abstract, target-binding table and conflict-of-interest disclosure were checked; the authors are employees of the compound’s developer.

  9. Meoni — DM2 binding sites — PubMed abstract
  10. Schmidt — sigma-1 structure — PubMed abstract
  11. Alon — sigma-2 and TMEM97 — PubMed abstract
  12. Nguyen — mouse model — PubMed abstract
  13. Carbonaro — DXM effects in humans — PubMed abstract
  14. Shram — ketamine comparison — PubMed abstract
  15. Monte — serotonin toxicity — PubMed abstract
  16. Harada — DXM and moclobemide — PubMed abstract
  17. Hamelin — diphenhydramine and CYP2D6 — PubMed abstract
  18. Gillman — serotonin toxicity — PubMed abstract
  19. Delsym — polistirex label — Official label

    The DailyMed label version published on 22 May 2026 was checked for formulation and ingredients.

  20. Ng — bromism — PubMed abstract
  21. Carliss — oral DXM in rats — PubMed abstract
  22. Tran — cellular changes in rats — PubMed abstract
  23. White — withdrawal of neurotoxicity claims — Historical archive

    The author’s 2004 response withdrawing his earlier claims was read.

  24. Qiu — MRI in DXM dependence — PubMed abstract
  25. Mutschler — dependence and withdrawal — PubMed abstract
  26. Olives — prolonged use and tolerance — PubMed abstract
  27. Chyka — clinical poisoning guideline — PubMed abstract
  28. Nuedexta — historical FDA label — Official label

    The historical 2010 FDA label was read for indication, ingredients and warnings.

  29. Auvelity — current label — Official label

    Indications, ingredients, interactions and mechanism were checked in the label revised in August 2026.

  30. FDA — new Auvelity indication — Official announcement

    The official FDA announcement of 30 April 2026 was read.

  31. Axsome — AXS-05 program announcement — Audit reference

    Listed in the audit bibliography; the primary document was not checked.

  32. Di Marco — juices and DXM pharmacokinetics — PubMed abstract
  33. Strauch — grapefruit juice and DXM metabolites — PubMed abstract
Reference

Open the source and related combinations →